Laboratory Products

  • Tumour Tissue Analysis Kits for Oncology Research Announced

Tumour Tissue Analysis Kits for Oncology Research Announced

Oct 17 2018 Read 421 Times

Roche has announced the global commercial launch of three new next-generation sequencing (NGS) AVENIO Tumor Tissue Analysis Kits - the AVENIO Tumor Tissue Targeted Kit, Expanded Kit and Surveillance Kit. The kits, which detect all four mutation classes in solid tumours, complement Roche’s NGS ctDNA kits for oncology research. The AVENIO research-use-only portfolio of ready-to-use kits provides reagents and software needed for labs to determine the genomic characteristics of solid tumours through a single DNA workflow.

“With the launch of these innovative assays we are pleased to further empower researchers around the world to continue to advance personalised oncology,” said Michael Heuer, CEO Roche Diagnostics. “These three ready-to-use AVENIO Tumor Tissue Analysis Kits enable researchers by providing relevant panel content that cover all four mutation classes to support the wide variety of cases that require genomic profiling, and complement the previously launched AVENIO ctDNA assays for liquid biopsy.”

Like the AVENIO ctDNA Analysis Kits launched in 2017, the AVENIO Tumor Tissue Analysis Kits are aligned with National Comprehensive Cancer Network (NCCN) guidelines to support oncology research. Researchers can now use the AVENIO family of NGS oncology assays to profile the genomic complexities of a variety of solid tumour types using formalin-fixed paraffin-embedded (FFPE) tissue or plasma to obtain detailed results from either workflow within five days.

“Cancer is a highly complex and dynamic disease, so the ability to obtain a detailed and accurate summary of the genomic profile of malignancies is critical. By combining the new AVENIO Tumor Tissue Kits with ctDNA kits containing exactly matched gene content, Roche has created an innovative new system not only for genomic profiling of solid tumours, but also to better understand how tumour heterogeneity and tumour burden change over time,” said Aadel Chaudhuri, MD, PhD, Assistant Professor of Radiation Oncology at Washington University School of Medicine.

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

International Labmate March 2019

March 2019

In This Edition Articles - Mobile Affinity Sorbent Chromatography Of Proteins - Integration of MS and UV Data for Peak Tracking in HPLC Method Development - Efficient heat transfer - power...

View all digital editions

Events

FORUMESURE

Mar 25 2019 Nantes, France

Bio-Europe Spring

Mar 25 2019 Vienna, Austria

Automaticon 2019

Mar 26 2019 Warsaw, Poland

Forum Labo Paris

Mar 26 2019 Paris, France

MEDLAB ASIA PACIFIC

Mar 26 2019 Suntec City, Singapore

View all events